Fresh analysis indicates that people who come off new weight-loss injections like Wegovy and Mounjaro may regain shed pounds at a significantly accelerated pace than those who halt conventional lifestyle plans.
Findings released in a leading health publication demonstrates that while obese people often shed substantial amounts of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users buying these drugs need to be cognizant of the danger of quick rebound weight gain when the medication ends," warns researcher Dr. Susan Jebb.
This pace of regain suggests a return to original weight within about one and a half years.
Weighing Treatments
The research, which reviewed dozens of trials involving over 9,000 of patients, contrasted the outcomes of the injectable medications with other pills.
Researchers point out that people who shed pounds through diet and exercise generally see a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Doctors propose the way of the injections accounts for the heightened rebound.
The injections copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations far above than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making excessive eating far more likely."
A Lifelong Disease?
The NHS suggest the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals say that, due to the significant potential of relapse, the therapy is often life-long.
This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the long-term character of excess weight," similar to managing diseases like hypertension.
User Accounts
Individuals who have discontinued the medication report a powerful return of cravings.
"It was like a trigger activating and I was suddenly ravenous," said an individual.
The struggle is worsened if users have not developed permanent lifestyle or habit modifications during treatment.
Significant Use
Survey data indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Finally, researchers caution that while GLP-1 drugs are potent agents for weight loss, they are not a magic fix and lasting health benefits hinges on combined behavioural support.
